A new member of the polyene family, N-dimethylaminoacetyl-partricin A 2-dimethylaminoethylamide diaspartate (SPA), was investigated and was found to be more effective than amphotericin B (i) in vivo by enhancing mouse resistance to cryptococcal meningoencephalitis and (ii) in vitro by potentiating the anticryptococcal activity of murine microglial cells.
The commensal yeast Cryptococcus neoformans is one of the most commonly encountered pathogens in AIDS patients (10) . Acquired by inhalation, C. neoformans can disseminate from the lung to the central nervous system, where it causes lifethreatening meningoencephalitis (10) . Even with aggressive chemotherapy, patient relapse and mortality rates are high (14) . Thus, there is a strong motive to develop novel drugs and/or immunotherapeutic protocols against this infection.
Currently, scant information exists on the potential role of local defenses against cerebral colonization by C. neoformans. In a previous report, we established an experimental model of intracerebral (i.c.) infection with C. neoformans that evolves into lethal meningoencephalitis (5) . Upon fungal opsonization the in vivo pathogenic burden of C. neoformans is reduced. Moreover, while pharmacological impairment of the phagocyte-mediated defenses is detrimental to the host, i.c. administration of picolinic acid, a potent macrophage costimulus (4, 7), or heat-killed C. neoformans (6) enhances host resistance to the subsequent lethal i.c. challenge with the fungus. In vitro studies further emphasize the role of cerebral phagocytes by documenting that microglial cells and astrocytes are proficient anticryptococcal effectors. In particular, using an in vitro-established murine microglial cell line (BV-2) (1), we found that maximal activity is achieved upon opsonization of the microorganisms and/or by gamma interferon pretreatment of the microglial cells (3) . Nevertheless, C. neoformans appears to counteract host defenses, irrespective of their stage of activation, in various ways, including melanization (3, 13) and capsule formation (8, 11) .
A new derivative of partricin, N-dimethylaminoacetyl-partricin A 2-dimethylaminoethylamide diaspartate (SPA), has been shown to exert potent antimicrobial activity in vitro against several microorganisms, including C. neoformans (12) . Its in vivo potential may be of interest because of the low level of toxicity recently ascribed to SPA in several animal models (unpublished data). In the present report, we investigated the impact of SPA (Società Prodotti Antibiotici, Milan, Italy) on host resistance to cerebral cryptococcosis both in vivo and in vitro. SPA was mixed with ascorbic acid (1:1 [wt/wt] ratio) prior to being dissolved and used. Amphotericin B (AmB) was included as a positive control, being among the most effective drugs for treating invasive fungal infection (9) . AmB was provided in vials containing 50 mg of AmB and 41 mg of sodium deoxycholate with 25.2 mg of sodium phosphate as a buffer. Both drugs were dissolved in sterile, nonpyrogenic 5% glucose in water and were stored at Ϫ20ЊC until in vitro use or in vivo intraperitoneal (i.p.) injection into mice in a volume of 0.1 ml/10 g of body weight. The in vitro activities (MICs) of both drugs were established for C. neoformans from the American Type Culture Collection (ATCC) (1 g/ml for SPA and 0.5 g/ml for AmB) as well as clinical isolates (0.5 to 2 g/ml for SPA and 0.5 to 2 g/ml for AmB).
With the intent of investigating the effects of SPA in vivo, we performed experiments in which female CD1 mice (age, 6 to 8 weeks) were challenged i.c. with a lethal dose of C. neoformans (10 5 yeast cells/mouse). A volume of 30 l per mouse was injected 1 mm laterally and posteriorly to the bregma at a depth of 2 mm. An encapsulated strain of C. neoformans (strain ATCC 11240) was used. Stock cultures were maintained by biweekly passages on Sabouraud dextrose agar at room temperature. Different doses of SPA were administered i.p. at 1 h postchallenge and daily for 4 days. AmB was given at the same doses and time schedules as SPA. The data in Table  1 indicate that both SPA and AmB enhanced the median survival times (MSTs) of C. neoformans-infected mice; the phenomena were dose dependent. In particular, at all dosages tested (range, 6 to 0.1 mg/kg of body weight), both drug treatments resulted in a significant enhancement of MSTs with respect to the MSTs for untreated control mice. Furthermore, at the highest dose tested (6 mg/kg), SPA and AmB treatments were able to protect the mice from lethal challenge, with 75 and 42.5% survivors, respectively.
In an attempt to emphasize the beneficial effects of the drugs, the treatment time was expanded to 9 days postinfection. As indicated in Table 2 , both SPA and AmB at doses of 6 mg/kg were able to protect 100% of the mice when the drugs were given daily for 9 consecutive days (MSTs, Ͼ60 days; there were no dead mice among 40 mice tested). When using a dose of 3 mg/kg, we found that SPA was more effective than AmB, with MSTs being 57 and 44, respectively (P Յ 0.01). Moreover, when evaluating the number of dead mice among the total number of mice tested, at 60 days, we found that SPA but not AmB treatment resulted in 38% survival at that time point. Placebo treatment failed to significantly alter MST or the range of survival times (Table 2) .
In parallel experiments, we investigated the numbers of CFU in the brains of SPA-and AmB-treated mice. Organs of individual mice were removed aseptically and were placed in a tissue homogenizer with 3 ml of sterile distilled water. The homogenized suspensions were seeded on Sabouraud dextrose agar plates (100 l/plate) in duplicate. The numbers of CFU were counted after 48 to 72 h of incubation at room temperature. Three determinations for three individual mice per group were performed. The results were expressed as the mean log 10 number of CFU per organ (Fig. 1) . Unlike the controls, both SPA-and AmB-treated mice had delayed brain colonization. The effects were dose and time dependent. In particular, the load in the brains of drug-treated mice was always significantly below that in the brains of the controls at all time points tested. A similar trend was also observed in terms of fungal load in the spleen and lung (data not shown). As depicted in Fig. 1 , when comparing SPA and AmB at doses of 6 mg/kg, we found that SPA was significantly more effective than AmB in containing the fungal burden in the brain, which dropped dramatically from day 4 on. When the 3-mg/kg doses were used, we found that both drugs were able to contain the load at below 10 4 CFU/brain up to day 21 postchallenge, a time in which the brains of mice in the control groups exhibited massive colonization (about 10 8 yeast cells). Under these conditions, AmB was statistically more effective than SPA. The apparent discrepancy between the numbers of CFU recovered and the MST observed with a dose of 3 mg/kg might be due to diverse long-lasting levels of SPA and AmB in biological fluids. Experiments are in progress to address this point.
Overall, our in vivo studies document the potency of SPA as an anticryptococcal agent whose in vivo toxicity was not detected under our experimental conditions (for SPA-treated and noninfected mice, MSTs were Ͼ60 days).
Increasing evidence ascribes to microglia a precious role as local defense elements against cerebral infections (2). In particular, using an established in vitro microglial cell line, we have shown that such immune cells exert anticryptococcal activity, the event being related to the fungal status (capsule size and melanization) and to the activation stage of the effector cell (1, 3) . With the purpose of investigating whether SPA or AmB might interfere with the accomplishment of such antic-FIG. 1. Time-and dose-dependent effects of SPA or AmB on the load of C. neoformans in the brains of C. neoformans-infected mice. Data are the mean log 10 numbers of CFU from three independent experiments in which three mice per group were used. Each brain was processed separately and plated in duplicate. The numbers of CFU were counted after 48 or 72 h at room temperature. Data were examined by analysis of variance by the GLM SAS procedure (11a). The P value was corrected for multiple comparisons (PЈ), where n is the number of preplanned comparisons. ‫,ء‬ P Յ 0.01 for SPA-or AmB-treated mice versus mice in untreated control groups (day 4 and day 21); ∧ , P Յ 0.01 for SPA-treated or AmB-treated mice versus mice in untreated control groups (day 1); A, P Յ 0.01 for SPA-treated versus AmB-treated groups; B, P Յ 0.05 for SPA-treated versus AmB-treated groups; C, P Յ 0.01 for AmB-treated versus SPA-treated groups; D, P Յ 0.05 for AmB-treated versus SPA-treated groups. (10 5 yeast cells/mouse). b Differences in survival times were evaluated between treated and untreated groups by the SAS life test procedure by using analysis of variance by GLM SAS (11a). P was corrected for multiple comparisons (PЈ) by the formula PЈ ϭ 1 Ϫ (1 Ϫ P) n , where n is the number of preplanned comparisons. c D/T, number of dead mice at 60 days over total number of animals tested. d P Յ 0.01 (drug-treated versus untreated mice). e P Յ 0.01 (SPA-treated versus AmB-treated mice).
ryptococcal activity, we performed in vitro experiments in which BV-2 microglial cells were exposed to SPA or AmB and then assessed for anticryptococcal activity. The BV-2 microglial cell line used in this study was obtained by infecting primary microglial cultures with a retrovirus carrying v-raf and v-myc (1). BV-2 cells were maintained by biweekly passages in RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum, gentamicin (50 g/ml), and L-glutamine (2 mM) (complete medium). Experimentally, BV-2 cells were plated at different concentrations (0.1 ml per well) in 96-well plates (Corning Glass Works, Corning, N.Y.), incubated with different doses of SPA or AmB for 3 or 24 h, and washed three times with complete medium. Then, the cells were infected with C. neoformans (10 5 yeast cells/ml), and after 24 h of coincubation at 37ЊC in an atmosphere containing 5% CO 2 , Triton X-100 (final concentration, 1%) was added to the wells, and the CFU assay was performed as detailed elsewhere (2) . Results were expressed as the percent reduction in CFU by the following formula: percent CFU inhibition ϭ [100 Ϫ (numbers of CFU in the experimental group/numbers of CFU in control cultures)] ϫ 100.
The data in Table 3 indicate that BV-2 cell exposure to SPA or AmB at a dose of Յ0.1 g/ml did not alter their anticryptococcal activities. Interestingly, when using a dose of 0.5 or 1.0 g/ml, we observed a dramatic reduction in the raw numbers of CFU, thus resulting in 100% inhibition in SPA-treated cells. Conversely, AmB treatment was still ineffective. A similar trend was observed by using different effector cell-to-target cell ratios or exposing BV-2 cells to the drugs for 24 h (data not shown). In parallel groups, BV-2 cells were preexposed or not preexposed to the drugs and then sonicated prior to the addition of C. neoformans. We found no anticryptococcal activity in sonicated control cells. Similarly, cell treatment with AmB, regardless of the dose used, or with SPA at doses of Յ0.1 g/ml was ineffective. In contrast, a few C. neoformans colonies and 100% CFU inhibition were detected in sonicated cells previously exposed to the highest doses of SPA (0.5 or 1.0 g/ml). These results demonstrate that microglial cell exposure to SPA results in the acquisition of potent antifungal activity. The fact that sonicated cells retain the same capacity as viable cells indicates that a carryover of SPA occurs, at least in our system, thus ensuring 100% blockage of fungal growth. Interestingly, such a phenomenon does not take place when AmB is used. Further studies are needed to explain the diverse behaviors of SPA and AmB. Nevertheless, it is fascinating to hypothesize that if the in vitro finding might have an in vivo counterpart, unlike AmB, SPA could provide a dual advantage to the host: first, by acting directly against the pathogen and, second, by accumulating on or in macrophages, whose killing is in turn potentiated.
In conclusion, our results provide evidence that a new derivative of the polyene family, SPA, is highly effective against C. neoformans. In particular, the capability of SPA to eradicate infection both in vitro (100% growth inhibition) and in vivo (Ͻ10 CFU/brain) renders this drug extremely interesting. These results, together with the minor toxic side effects associated with SPA administration (data not shown), strongly support the forthcoming use of SPA in clinical trials. a BV-2 cells were incubated with different concentrations of SPA or AmB for 3 h. Then, BV-2 cells were washed three times with medium and plated with C. neoformans (effector cell-to-target cell ratio, 5:1). In parallel groups, BV-2 cells, treated or not treated with SPA or AmB for 3 h, were sonicated and then C. neoformans was added. As a baseline control group, C. neoformans was plated in medium alone. Each group was plated in triplicate, and the numbers of CFU were assessed 24 h later. Data are the means Ϯ standard deviations of three independent experiments. Statistical analysis was performed by Student's t test.
b The recovery for C. neoformans plated alone was 78,660 Ϯ 6,027 CFU. c ND, not detectable. 
